According to the "2021 Pink Report on Women's Breast Health in China", the number of new breast cancer cases around the world reached 2.26 million in 2020, which has displaced lung cancer to become the most leading diagnosed cancer worldwide. China recorded 416,000 new breast cancer patients in 2020, with an average of 1 case diagnosed every 76 seconds. The incidence rate is increasing year by year, and the age of patients tends to be younger. Breast cancer has become the top threat of women's health.

Aurora Healthcare US Corp (Aurora) which was founded in Boston, USA in 1999, has strong influence at home and abroad. Aurora has become a leader in the breast health field after years of development by introducing cutting-edge breast examination technology while integrating resources and making specialization.

After months of consultation and professional discussion, the Sichuan Branch of Aurora (Chengdu SunDoctor Aurora Medical Technology Ltd.) and Xindu Branch of China Life Insurance Company Limited (China Life) have jointly developed a dedicated insurance product for breast precision diagnosis which has been officially launched recently. It means that Aurora has made substantial progress in exploring the HMO (Health Maintenance Organization) model for breast disease. Through cooperate with the professional commercial insurance enterprise, Aurora has made it possible to be put into practice from breast diseases prevention and screening to precision diagnosis, from diagnosis and treatment to innovative payment.

This dedicated insurance product with a premium of about 200 yuan, mainly covers the cost of $1,500 for pathological examinations if a woman's imaging results are interpreted as BIRADS 4 or 5 (a classification of risky and requiring pathological examinations according to breast cancer screening guidelines) after the examination by Aurora dedicated breast MRI.

This insurance product is mainly aimed at patients who are detected to be positive (BIRADS 4 or 5) by ultrasound examination. The purpose is to eliminate these patients' anxiety and allow those who really need to undergo pathological examination could get compensation to ease their burden, and further reduce the drop-out rate for positive patients to accept early diagnosis.

At the same time, Aurora dedicated breast MRI can not only greatly reduce missed diagnosis, but also minimize the false positive rate. Through more than 20 years of clinical experience in Western countries such as the United States, as well as 10 years of clinical data in Taiwan, Aurora has shown that many positive patients detected by ultrasound were instead lowered in grade through the examination by dedicated breast MRI. Some patients who were classified as BIRADS 4 by ultrasound have been lowered to BIRADS 3, relieving many patients of surgical biopsy and worries. This is another contribution of Aurora dedicated breast MRI.

As a global supplier of dedicated breast MRI, Aurora has installed more than 80 units around the world. Aurora dedicated breast MRI is especially suitable for Oriental women with dense breast based on its capable to diagnose precisely. Its accuracy and sensitivity are higher than that of whole-body MRI. It can detect tumors smaller than 1mm, which not only greatly improves the early diagnosis rate, but also enables early detection of microscopic breast lesions to prevent the occurrence of breast cancer. Compared with the whole-body MRI, Aurora dedicated breast MRI also makes the patients feel more comfortable during the examination and shortens examination time.

As a large state-owned financial and insurance group, China Life is a benchmark enterprise in the insurance industry. Its Xindu Branch and Aurora's Sichuan Branch have joined hands to launch this insurance product, which is not only a commercial cooperation, a joint exploration of an innovative HMO model for breast disease, but also a commitment to social responsibility. Through the intervention of insurance, Aurora and China Life share the common expectation to change the payment model, reduce the patient's payment burden, promote women to actively accept breast screening. Furthermore, their cooperation echoes the national "three early" breast cancer prevention plan (early screening, early diagnosis and early treatment), to increase the early diagnosis rate and the breast preservation rate, reduce mortality rate and treatment costs, and improve the breast cancer patients' quality of life.